Literature DB >> 25906681

Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice.

Stanley M H Chan1, Xiao-Yi Zeng1, Ruo-Qiong Sun1, Eunjung Jo1, Xiu Zhou1, Hao Wang1, Songpei Li1, Aimin Xu2, Matthew J Watt3, Ji-Ming Ye4.   

Abstract

Hepatic steatosis is often associated with insulin resistance as a hallmark of the metabolic syndrome in the liver. The present study investigated the effects of PPARα activation induced by fenofibrate (FB) on the relationship of insulin resistance and hepatic steatosis in mice fed a high-fat (HF) diet, which increases lipid influx into the liver. Mice were fed HF diet to induce insulin resistance and hepatic steatosis with or without FB. FB activated PPARα and ameliorated HF diet-induced glucose intolerance and hepatic insulin resistance without altering either hepatic steatosis or inflammation signaling (JNK or IKK). Interestingly, FB treatment simultaneously increased fatty acid (FA) synthesis (50%) and oxidation (66%, both p<0.01) into intermediate lipid metabolites, suggesting a FA oxidation-synthesis cycling in operation. Associated with these effects, diacylglycerols (DAGs) were sequestered within the lipid droplet/ER compartment, thus reducing their deposition in the cellular membrane, which is known to impair insulin signal transduction. These findings suggest that the reduction in membrane DAGs (rather than total hepatic steatosis) may be critical for the protection by fenofibrate-induced PPARα activation against hepatic insulin resistance induced by dietary fat.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DAG repartitioning; FA oxidation; FA synthesis; Insulin signaling; PPARα

Mesh:

Substances:

Year:  2015        PMID: 25906681     DOI: 10.1016/j.bbadis.2015.04.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.

Authors:  Tsuyoshi Goto; Mariko Hirata; Yumeko Aoki; Mari Iwase; Haruya Takahashi; Minji Kim; Yongjia Li; Huei-Fen Jheng; Wataru Nomura; Nobuyuki Takahashi; Chu-Sook Kim; Rina Yu; Shigeto Seno; Hideo Matsuda; Megumi Aizawa-Abe; Ken Ebihara; Nobuyuki Itoh; Teruo Kawada
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

Review 2.  Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Trends Pharmacol Sci       Date:  2017-05-24       Impact factor: 14.819

3.  Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Authors:  Aowen Zhuang; Felicia Yt Yap; Clinton Bruce; Chris Leung; Manuel R Plan; Mitchell A Sullivan; Chandana Herath; Domenica McCarthy; Karly C Sourris; Phillip Kantharidis; Melinda T Coughlan; Mark A Febbraio; Mark P Hodson; Matthew J Watt; Peter Angus; Benjamin L Schulz; Josephine M Forbes
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

4.  PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study.

Authors:  Xiaomeng Feng; Xia Gao; Yumei Jia; Yuan Xu
Journal:  Diabetes Ther       Date:  2017-03-30       Impact factor: 2.945

5.  Chronic activation of PPARα with fenofibrate reduces autophagic proteins in the liver of mice independent of FGF21.

Authors:  Eunjung Jo; Songpei Li; Qingning Liang; Xinmei Zhang; Hao Wang; Terence P Herbert; Trisha A Jenkins; Aimin Xu; Ji-Ming Ye
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

6.  Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).

Authors:  Li-Jun Ning; An-Yuan He; Dong-Liang Lu; Jia-Min Li; Fang Qiao; Dong-Liang Li; Mei-Ling Zhang; Li-Qiao Chen; Zhen-Yu Du
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

7.  Association of muscle lipidomic profile with high-fat diet-induced insulin resistance across five mouse strains.

Authors:  Magdalene K Montgomery; Simon H J Brown; Todd W Mitchell; Adelle C F Coster; Gregory J Cooney; Nigel Turner
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

8.  The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Authors:  Shengjie Tang; Fang Wu; Xihua Lin; Weiwei Gui; Fenping Zheng; Hong Li
Journal:  J Diabetes Res       Date:  2020-05-04       Impact factor: 4.011

9.  PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance.

Authors:  Jia Liu; Rui Lu; Ying Wang; Yanjin Hu; Yumei Jia; Ning Yang; Jing Fu; Guang Wang
Journal:  PPAR Res       Date:  2016-02-29       Impact factor: 4.964

10.  The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.

Authors:  Masaya Araki; Yoshimi Nakagawa; Asayo Oishi; Song-Iee Han; Yunong Wang; Kae Kumagai; Hiroshi Ohno; Yuhei Mizunoe; Hitoshi Iwasaki; Motohiro Sekiya; Takashi Matsuzaka; Hitoshi Shimano
Journal:  Int J Mol Sci       Date:  2018-07-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.